Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Schrodinger Inc (SDGR) USD0.01

Sell:$60.43 Buy:$60.51 Change: $0.27 (0.45%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$60.43
Buy:$60.51
Change: $0.27 (0.45%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$60.43
Buy:$60.51
Change: $0.27 (0.45%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Schrodinger, Inc. provides computational software solutions for drug discovery to the biopharmaceutical industry. The Company operates through two segments: Software and Drug Discovery. The Software segment is focused on licensing the Company’s software for molecular discovery. The Drug Discovery segment is focused on building a portfolio of preclinical and clinical drug programs, internally and through collaborations. Its platform integrates solutions for predictive modeling, data analytics and collaboration. Its wholly-owned programs include SDGR1, SDGR2, SDGR3, SDGR4 and SDGR5. SDGR1 and SDGR2 drug discovery programs are focused on targets that mediate deoxyribonucleic acid (DNA) repair, cell cycle regulation, replication stress responses, and apoptosis, or programmed cell death. SDGR3, SDGR4 and SDGR5 drug discovery programs are focused on genetically-defined cancers.

Contact details

Address:
1540 BROADWAY, 24TH FLOOR
NEW YORK
10036
United States
Telephone:
+1 (503) 2991150
Website:
https://www.schrodinger.com

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
SDGR
ISIN:
US80810D1037
Market cap:
$4.26 billion
Shares in issue:
79.90 million
Sector:
Health Care Technology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Ramy Farid
    President, Chief Executive Officer, Director
  • Joel Lebowitz
    Executive Vice President, Chief Financial Officer
  • Kenneth Lorton
    Executive Vice President, Chief Technology Officer
  • Robert Abel
    Executive Vice President, Chief Computational Scientist, and Head of Modeling R&D
  • Karen Akinsanya
    Executive Vice President, Chief Biomedical Scientist, Head of Discovery R&D
  • Yvonne Tran
    Executive Vice President, Chief Legal Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.